Mesoporous Silica Nanoparticles With Customized Drug Ratio/Loading for Effective Treatment of Gemcitabine‐Resistant Pancreatic Tumors

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a 5‐year survival rate below 13% and limited treatment options due to rapid metastasis and pronounced chemoresistance. Gemcitabine (Gem) remains a first‐line chemotherapy agent; however, its clinical efficacy is hindered...

Descripció completa

Dades bibliogràfiques

Autors principals:	Tamanna Binte Huq, Sudip Kumar Dam, Doaha Awad, Punnya Anil Kumar Jeeja, Farzana Ferdous, Juan L. Vivero‐Escoto
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley-VCH 2026-07-01
Col·lecció:	Advanced NanoBiomed Research
Matèries:	combination therapy controlled release gemcitabine resistance mesoporous silica nanoparticles pancreatic cancer
Accés en línia:	https://doi.org/10.1002/anbr.202500255
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!